HAVEN 4 trial

May 25, 2018May 25, 2018

Hemlibra Looks to Reach ‘Ultimate Goal’ of Treating All with Hemophilia A and with Choice in Dosing, Genentech Director Says

News

Should regulatory authorities agree with favorable results from Genentech’s ongoing Phase 3 studies of Hemlibra (emicizumab-kxwh), hemophilia A patients may have a treatment they can use regardless of inhibitor status, with ... Read more

February 2, 2018February 2, 2018

Hemlibra Data Show Sustained Bleed Reductions in Hemophilia A Patients with Inhibitors

News

Clinical trials of Hemlibra (emicizumab-kxwh) continue to show significant reductions in bleeding episodes in patients with hemophilia A with inhibitors, Genentech recently announced. Data from Hemlibra’s clinical development program were ... Read more

December 8, 2017December 8, 2017

Genentech’s Hemlibra Maintains Strong Bleeding Control Results in Phase 3 Trial, Interim Analysis Shows

News

Injection of Hemlibra (emicizumab-KXWH) every four weeks helps control bleeding in hemophilia A patients, an interim analysis of the Phase 3 HAVEN 4 study shows. The results, announced by Genentech, are in agreement ... Read more

Pin It on Pinterest